Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 17/20 | 0.64 |
| ▸ | ACE | P12821 | 7/20 | 0.64 |
| ▸ | MMEL1 | Q495T6 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18598040 | 0.89 | MME (0.70) | MMEACEMMEL1 | |
| SCHEMBL14890588 | 0.89 | MME (0.70) | MMEACEMMEL1 | |
| SCHEMBL16011776 | 0.89 | MME (0.82) | MMEACEMMEL1 | |
| SCHEMBL14891211 | 0.89 | MME (0.82) | MMEACEMMEL1 | |
| SCHEMBL18597739 | 0.89 | MME (0.82) | MMEACEMMEL1 | |
| SCHEMBL18783219 | 0.88 | MME (0.69) | MMEACEMMEL1 | |
| SCHEMBL16270268 | 0.88 | MME (0.69) | MMEACEMMEL1 | |
| SCHEMBL14918910 | 0.85 | MME (0.55) | MMEACEMMEL1 | |
| SCHEMBL14890662 | 0.85 | MME (0.55) | MMEACEMMEL1 | |
| SCHEMBL16024098 | 0.85 | MME (0.55) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.